You ever wonder how it is that these biotechs eventually end up with 90% institutional ownership before they send the shares screaming upward to increase in price 5-fold? This is how they do it. They do their absolute best to wipeout all retail holders, then when they have accumulated huge percentages of the companies, then and only then do they suddenly realize that gee this biotech is really worth 5 times what they were saying it was worth before. Nothing to do but let them play their filthy manipulative games until they have achieved their goals and are ready, or at times forced, to let the share price rise. I have no doubt, if the market would roll over heard, as the shorts have been expecting, they will redouble their shorting, even naked short, to crush the share price......they are just waiting and hoping for that long overdue correction. When the market goes up then they just try and hold their gains thinking time, for now, is still on their side. This is the huge negative about the deal which Al signed.....there was no equity stake at like $11 which would have upheld the share price.
Lower the Better as far as I am concerned! Gotta appreciate those incorrigible rascally shorts!! ; )
It's a gift Kevin.....relax, they aren't likely going to change at this point. These guys at MNKD sadly seem to be pretty much of the laissez-faire style of mngt., or as others refer to it as the Doris Day school (whatever will be will be). Nothing we can do, it is in SNY hands now, and for all we know SNY has specifically requested they pretty much keep their mouths shut.
I would sure love the opportunity to load up at under $5 sometime before lift-off.
Still very early with this company, volume is pretty low, they just did a R/S, plus they are real low on money (so could be a dilution before long...otoh, they have supposedly submitted data for publication and are also supposedly in process for uplisting. Just an alert to any interested is all.
Interesting using a 'variable' discount, and of course MNKD shares, if Afrezza sales reach our expectations, won't be sporting a P/S ratio of 10, at least not for the first 3 years or so until taxes kick in and adoption rates drop out of vertical mode.
Sentiment: Strong Buy
You are correct - my bad....but my reaction still got me out at $9.77, and now back in at $9.05
If it was a planned sale, that is totally different. Figured with the reaction and all the posts, that it Wasn't planned.
Just makes no sense.
Anything is possible, and I would expect more like a 5% stake.....one has to wonder why, if that is part of the deal, such a share price supportive announcement wasn't made at the time of the SNY deal announcement, but simply with the caveat of government approval contingent. The shorts have played their hand way to boldly, imo, to not have been privy to crucial deal specific information which they shouldn't have had...and notice they don't seem too worried even now.
Of course even a minor equity stake buy-in at say $10 by SNY would have sufficed even better.....of course that didn't happen either, but then we wouldn't be afforded this current opportunity to increase shares at under $7, and who knows - it may be under $6 before liftoff; gotta stay nimble and always have at least a plan 'B' with biotech.
Wow! Great job cp....maybe pfg was a bit on the conservative side with the $1700 figure, hope yours are closer to accurate.
$500 ballpark per patient annually is considerably more than I was figuring, but if this has been confirmed by Matt then so be it. My model calls for Afrezza to be used by roughly 8 million diabetics by 2019...at $500 per, that works out to $4B. Slapping a very conservative P/S metric of 10 on that and dividing by say 500 shares gives you $80 p/share; discounting 20% per year gives us a current "fair" value of $26
Sentiment: Strong Buy
pfg's final number, wholesale with discounts was roughly $1700 annually per patient - wholesale with discounts.
Are you saying that Matt has confirmed MNKD's 'share' will be ballpark at about $500 per patient?
What are you estimating the profit margin for SNY on Afrezza sales?
For a couple years I would keep them on mute to avoid the idiocy, and wait for Santelli - now, don't even bother turning them on at all.
Have fun getting ut of this one shorts.......lol
Agree. CUR is my largest holding. Not a large institutional holding yet, but the shares are going to go vertical with the next positive announcement regarding P2 efficacy or the FDA granting the go-ahead for the Phase 3 trial.
Didn't you get the memo? Mikey says $50 in 6 months, and $500 in 3 years......so of course the deal for the 'rest' of MNKD has to be better - I mean like just do the math dude! Go Mikey!!! See there is less of MNKD now available sooo naturally, by the laws of supply and demand, with the 'availability' of MNKD so reduced, well the remaining shares are so much more valuable!